Bacterial Vaginosis, HIV Infections
Conditions
Keywords
Genital immunology, HIV susceptibility, Microbiome, Bacterial vaginosis, Virus entry assay
Brief summary
A non-randomized, interventional, longitudinal clinical study to quantify the impact of bacterial vaginosis treatment on HIV susceptibility and genital immunology in Kenyan women.
Detailed description
Bacterial Vaginosis (BV), defined as an alteration in the normal vaginal bacteria (microbiome), is characterized by a reduction of hydrogen peroxide-producing gram-positive lactobacilli and overgrowth of gram-negative and anaerobic bacteria. BV is more prevalent in SSA and usually recurs soon after treatment. BV is associated with vaginal inflammation, an increased HIV acquisition risk among uninfected women, and increased HIV transmission to the male sexual partner of a co-infected woman. Therefore, BV may be responsible for up to 17% of HIV transmission events in SSA. There are several hypotheses for the mechanisms by which BV may increase the risk of HIV acquisition. These include the disruption of mucosal barrier, alteration of protective innate immunity, and increased number and/or susceptibility of HIV target cells in the genital mucosa. Longitudinal studies that address the mechanisms by which the vaginal microbiota alters host mucosal immunology and HIV risk will help us better understand the impact of BV and it's treatment on mucosal immunology and HIV susceptibility. The goal of this non-randomized, interventional, longitudinal clinical study is to use a novel ex vivo HIV infectivity assay developed in the Kaul lab to quantify the effect of BV and its treatment on HIV susceptibility and genital immunology in HIV-uninfected women from Nairobi, Kenya. Fifty HIV, STI-uninfected women with bacterial vaginosis on Nugent scoring will be provided with one week of metronidazole 400mg po three times daily (as per Kenyan National Guidelines). Cytobrush and vaginal SoftCup sampling will be performed at baseline and 4 weeks after treatment initiation, at the same stage of the menstrual cycle. The primary endpoint will be pseudovirus entry into cervix-derived CD4+ T cells. Secondary endpoints will include a pre-defined cervico-vaginal inflammation score; genital CD4+ T cell immune characteristics; the genital microbiome; the genital proteome.
Interventions
DRUGMetronidazole
Participants will be provided with oral metronidazole 400mg po tid for one week, and followed up one month after treatment initiation.
Sponsors
University of Toronto
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
1. Participants are over 18 years of age, not pregnant and willing to give informed consent, and answer short questionnaires on economic status, and sexual risk behavior. 2. Willing to comply with the requirements of the protocol 3. HIV and classical STI (see below) negative 4. test positive for BV, defined as Nugent score from 7-10 5. willing to take oral metronidazole twice a day for 7 days 6. willing to abstain from alcohol during and for 48 hours after metronidazole treatment
Exclusion criteria
1. HIV infected 2. Deemed by physician to be unlikely to complete study protocol. 3. Pregnant. 4. Irregular menstrual cycle, or actively menstruating at the time of genital sampling. 5. Tested positive for classical STIs or having genital ulcers 6. Prior hysterectomy 7. Contraindication, allergy or intolerance to use of metronidazole
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent HIV pseudovirus entry into cervical CD4+ T cells. | up to 8 months | The percentage of cervical CD4+ T cells per cytobrush infected ex vivo by an HIV pseudovirus construct will be quantified by flow cytometry. |
| Total number of cervical CD4+ T cells infected ex vivo with HIV. | up to 8 months | The total number of cervical CD4+ T cells per cytobrush infected ex vivo by an HIV pseudovirus construct will be quantified by flow cytometry. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| A genital inflammation score based on genital levels of pro-inflammatory cytokines and chemokines. | up to 8 months | Level of 14 genital cytokines/chemokines (GM-CSF, IL-1a, IL-8, MCP-1, MIG, MIP-3a, RANTES, IL-10, IL-17, IL-1b, IL-6, IP-10, MIP-1b, TNF-a) will be combined into a genital inflammation score \[Arnold K et al, Muc Immunol, 2015\]. |
| The cervico-vaginal microbiome. | up to 8 months | The cervico-vaginal microbiome will be assessed by 16s rRNA sequencing before and after metronidazole therapy. |
| Genital proteome analysis. | up to 8 months | The genital proteome will be assessed by mass spectroscopy before and after metronidazole therapy. |
| CD4+ expression of pre-defined HIV susceptibility markers | up to 8 months | Surface expression of CCR5, CD69, a4b7 and a4b1 by endocervical CD4 T cells before and after metronidazole therapy. |
Countries
Kenya
Outcome results
None listed